Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib (Q60051674)

From Wikidata

Revision as of 19:16, 23 May 2024 by Emijrpbot (talk | contribs) (‎Changed label, description and/or aliases in 53 languages: BOT - Adding descriptions (53 languages): ar, bg, bn, ca, cs, da, el, eo, es, et, fa, fi, gl, he, hu, it, ja, ka, ko, lt, nan, nb, nn, oc, pl, pt, pt-br, ro, ru, sk, sq, sr, sr-ec, sr-el, sv, tg, tg-cyrl, th, tl, tr, ur, vi, wuu, yue, zh, zh-cn, zh-hans, zh-hant, zh-hk, zh-mo, zh-my, zh-sg, zh-tw)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 22 November 2018

Language	Label	Description	Also known as
English	Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib	scientific article published on 22 November 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Chang Wook Jeong

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

12

object named as

Seong Il Seo

0 references

author name string

Dong Deuk Kwon

5

0 references

Jun Eul Hwang

6

0 references

Woo Kyun Bae

7

0 references

Chang Wook Jeong

9

0 references

Cheol Kwak

10

0 references

Cheryn Song

11

0 references

Seok-Soo Byun

13

0 references

Sung-Hoo Hong

14

0 references

Jinsoo Chung

15

0 references

language of work or name

0 references

publication date

22 November 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Journal of Korean Medical Science

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

33

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

51

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

e325

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 January 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rising incidence of small renal masses: a need to reassess treatment effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30546281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3346/JKMS.2018.33.E325

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546281%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60051674&oldid=2162702239"